STOCK TITAN
  1. Home
  2. Sec-filings
  3. IONS
  4. [Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity

Ionis Pharmaceuticals (NASDAQ: IONS) EVP reports stock sale and RSU grants

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple equity transactions in January 2026. On January 15, 2026, 17,377 shares of common stock were acquired upon vesting of restricted stock units at an exercise price of $0.0, and on January 16, 2026, 8,353 shares of common stock were sold in an automatic sale to cover tax withholding at a weighted average price of $75.95.

Devers also received 25,800 Performance Restricted Stock Units, representing the maximum that may be earned based on a three-year performance period, and 9,675 Restricted Stock Units that vest in four equal annual installments. Following these transactions, she directly beneficially owned 26,518 shares of common stock, 47,800 Performance RSUs, and 52,704 RSUs, each RSU representing a contingent right to one share of Ionis common stock or its cash equivalent.

Positive

  • None.

Negative

  • None.
Insider Devers Shannon L.
Role EVP, Chief Human Resources Ofc
Sold 8,353 shs ($634K)
Type Security Shares Price Value
Sale Common Stock 8,353 $75.95 $634K
Grant/Award Performance Restricted Stock Units 25,800 $0.00 --
Exercise Restricted Stock Unit 17,377 $0.00 --
Grant/Award Restricted Stock Unit 9,675 $0.00 --
Exercise Common Stock 17,377 $0.00 --
Holdings After Transaction: Common Stock — 26,518 shares (Direct); Performance Restricted Stock Units — 47,800 shares (Direct); Restricted Stock Unit — 43,029 shares (Direct)
Footnotes (1)
  1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.94 to $75.96 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Devers Shannon L.
(Last) (First) (Middle)
2855 GAZELLE COURT
(Street)
CARLSBAD CA 92010
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IONIS PHARMACEUTICALS INC [ IONS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Human Resources Ofc
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 M(1) 17,377(1) A $0.0 34,871 D
Common Stock 01/16/2026 S(2) 8,353(2) D $75.95(3) 26,518 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Units(4) $0.0 01/15/2026 A 25,800 01/15/2029(5) (5) Common Stock 25,800 $0.0 47,800 D
Restricted Stock Unit $0.0(6) 01/15/2026 M 17,377 01/15/2026(7) (7) Common Stock 17,377 $0.0 43,029 D
Restricted Stock Unit(8) $0.0(6) 01/15/2026 A 9,675 01/15/2027(7) (7) Common Stock 9,675 $0.0 52,704 D
Explanation of Responses:
1. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.94 to $75.96 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
4. Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
5. The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.
6. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
7. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.
8. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
By: Patrick R. O'Neil, attorney-in-fact For: Shannon L. Devers 01/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in the January 2026 Form 4 for IONIS PHARMACEUTICALS INC (IONS)?

The Form 4 reports transactions by Shannon L. Devers, who serves as EVP, Chief Human Resources Officer of Ionis Pharmaceuticals Inc.

What common stock transactions did Shannon Devers report for IONIS (IONS)?

Devers reported acquiring 17,377 shares of common stock on January 15, 2026 upon RSU vesting at $0.0 and selling 8,353 shares on January 16, 2026 at a weighted average price of $75.95 in an automatic sale to cover tax withholding.

What equity awards were granted to Shannon Devers in the IONIS (IONS) Form 4?

Devers was granted 25,800 Performance Restricted Stock Units that may vest after a three-year performance period based on relative total shareholder return, and 9,675 Restricted Stock Units that vest in four equal annual installments.

How many IONIS (IONS) shares does Shannon Devers own after the reported transactions?

After the reported transactions, Devers directly beneficially owned 26,518 shares of common stock of Ionis Pharmaceuticals Inc.

How many RSUs and PRSUs does Shannon Devers hold after the IONIS (IONS) Form 4 transactions?

Following the transactions, Devers held 47,800 Performance Restricted Stock Units and 52,704 Restricted Stock Units, each representing a contingent right to receive one share of Ionis common stock or its cash equivalent.

What is the purpose of the stock sale reported by Shannon Devers for IONIS (IONS)?

According to the filing, the 8,353-share sale at a weighted average price of $75.95 was an automatic sale to cover required tax withholding obligations related to restricted stock unit vesting under the company’s equity incentive plan.